Seeking Alpha

Endocyte soars after Q3 update

  • Endocyte (ECYT +30.1%) is up nicely following the company's Q3 report and update. Net loss for the period was $0.08/share. Revenue was $16.6M (Merck collab).
  • PROCEED (vintafolide/etarfolatide in platinum resistant ovarian cancer) enrollment is on track. Interim analysis in Q2 2014.
  • TARGET top-line read-out expected in Q1 2014. See here for more on TARGET.
  • The FDA has accepted an IND for EC1456.
  • CHMP opinion still expected next month or in January.
  • Cash and equivalents guidance for end of year: Unchanged at $145-160M. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector